BERLIN, July 3, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today the appointments of Zsolt Lavotha and Dr. Gunter Stock to Jerini's Supervisory Board, as elected at the company's June 30th General Shareholders' Meeting.
Zsolt Lavotha is President and Chief Executive Officer of Orexo AB, a pharmaceutical company based in Uppsala, Sweden. "I am impressed by all that Jerini's management has accomplished so far and delighted to have the opportunity to join the Supervisory Board as the company moves into an exciting new stage in its development," said Lavotha.
Dr. Gunter Stock, a member of the Management Board of Schering AG from 1989-2005, was recently elected President of the Berlin-Brandenburg Academy of Sciences. "My personal association with Jerini goes back quite a few years, and it is my privilege to join the company and serve on its Supervisory Board," stated Stock.
"Both Zsolt Lavotha and Gunter Stock bring with them extensive experience in the pharmaceutical industry and will provide important support at this pivotal time in Jerini's development," said Jens Schneider-Mergener, CEO of Jerini. "With the planned 2007 market launch of our lead product, Icatibant, the company is now entering an important new phase." Dr. Peter Johann, Managing General Partner, NGN Capital and Dr. Klaus Stockemann, Partner, 3i Deutschland GmbH ended their terms as members of the Jerini Supervisory Board.
About Jerini AG
Jerini AG is a pharmaceutical company based in Berlin, Germany focusing on the discovery and development of peptide-based drugs. Having recognized the potential of peptides as natural starting molecules for drug discovery, the company has developed state-of-the-art technologies to identify and transform peptides into drugs. The company's lead product, Icatibant, is currently in Phase III clinical trials for the treatment of hereditary angioedema (HAE). It is estimated that between 1:10,000 and 1:50,000 people worldwide are affected by this disease. Based on its technology platform, Jerini has established several in-house development programs, which address indications within ophthalmology, oncology, and inflammatory therapeutic areas. The most advanced of these programs targets age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. ISIN: DE0006787476
For questions, please contact: Stacy Wiedenmann Director Investor Relations & Corporate Communications Jerini AG Invalidenstr. 130 10115 Berlin T + 49 - 30 - 97893 - 285 X + 49 - 30 - 97893 - 105 wiedenmann@jerini.com